MedElevator
Войти в исследования Long-acting cabotegravir and rilpivirine in people with HIV and obesity: Real-world outcomes from the RELATIVITY cohort.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Troya Jesús, Mican Rafael, Galindo María José, Bisbal Otilia, Romero Lucía, Torralba Miguel, Buzón-Martín Luis, de la Fuente Sara, Fanjul Francisco, Rodríguez Adrián, Cabello Alfonso, Sanjoaquin Isabel, Del Carmen Navarro María, Aguilera María, Hidalgo-Tenorio Carmen, Morano Luis Enrique, Martínez Clara, Poquet Inmaculada, Bernal Enrique, Caballero Ruth, Cabello-Clotet Noemí, Fernández Analuz, Del Carmen Montero María, Vivancos-Gallego María Jesús, Tejerina Francisco, Soria Guillermo, de Zárraga Miguel Alberto, Cairó Mireia, Romero Alberto, Cabo Rebeca, Arenas Víctor, Sepúlveda María Antonia, Alcaraz Antonia, Escrich Cristina, González-Rico Claudia, Ferreira Eva María, Valentín Beatriz, Muelas-Fernández Magdalena, Llenas-García Jara, García Sara, Losa-García Juan Emilio, Alonso Bárbara, Sanz José, Gutiérrez Félix, Vázquez Nuria, Corte Juan José, Garcinuño María Ángeles, Gainzarain Juan Carlos, Estébanez Miriam, Pedrero-Tomé Roberto, Montes María Luisa
Аннотация
METHODS: We conducted a multicentre, ambispective study (RELATIVITY cohort, Spain) of virologically suppressed PWH with BMI ≥ 30 kg/m2 who switched to LAI CAB + RPV. This study characterized this population and evaluated the factors associated with virologic outcomes, tolerability and adherence using Kaplan-Meier analysis.
RESULTS: Among the 3,203 individuals recruited in the RELATIVITY cohort, 57 were excluded due to detectable HIV RNA at the time of switching to LAI CAB+RPV, and 3,146 were finally included, all of whom had HIV RNA levels <50 copies/mL at baseline. BMI data were available for 2,736 participants, of whom 362 (11.5%) had a BMI ≥30 kg/m2 and 2,374 had a BMI <30 kg/m2. Obese participants were older (median age 48 vs. 45 years) and included a higher proportion of women (21.9% vs. 13.7%). Comorbidities included dyslipidaemia (36.7%), hypertension (22.9%), diabetes (11.6%), chronic lung disease (6.4%), MASLD (5.5%) and coronary disease (3.3%). The main reasons for switching included quality-of-life improvement (49.2%), patient requests (35.4%), and therapy simplification (26%). VF was rare, occurring in 1.1% of obese individuals and 0.6% of non-obese participants over a median follow-up of 13.8 months (p = 0.284). Emergent resistance mutations were detected in 2/4 VF in obese participants. The discontinuation rate was low across all study groups. Among participants with obesity, local adverse events accounted for 1.9% of discontinuations, systemic adverse events for 0.8%, and other causes for 3.9% of discontinuations. In this subgroup, 72.9% of injections were administered using a 38-mm needle. Injection adherence was excellent, with 83.1% of participants with obesity achieving full (100%) coverage and an additional 16.3% maintaining 90-99.9% coverage.
CONCLUSIONS: In this real-world cohort, LAI CAB + RPV was safe and effective in PWH with obesity, with comparable VF rates, tolerability, and adherence to participants without obesity. These findings support the use of LAI CAB + RPV across diverse PWH populations, including those with a BMI ≥ 30 kg/m2, and highlight its feasibility in PWH with multiple comorbidities.